Anika Therapeutics (ANIK) Revenue (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of Revenue data on file, last reported at $29.6 million in Q1 2026.

• On a quarterly basis, Revenue rose 13.16% year-over-year to $29.6 million in Q1 2026; TTM through Mar 2026 was $116.3 million, a 0.67% decrease from a year earlier, with the FY2025 full-year figure at $112.8 million, down 5.91% from the prior year.
• Revenue for Q1 2026 stood at $29.6 million, down from $30.6 million in the prior quarter.
• Over the last five years, Revenue for ANIK reached as high as $44.3 million in Q2 2023 and fell as low as -$2.9 million in Q4 2023.
• Historically, Revenue has averaged $29.2 million across 5 years, with a median of $30.6 million in 2024.
• Across the five-year window, Revenue slumped 107.78% in 2022 and jumped 1155.61% in 2024, its largest moves.
• Year by year, Revenue stood at -$2.8 million in 2022, then dropped by 4.02% to -$2.9 million in 2023, then soared by 1155.61% to $30.6 million in 2024, then grew by 0.04% to $30.6 million in 2025, then fell by 3.28% to $29.6 million in 2026.
• Per Business Quant data, the three most recent Revenue figures were $29.6 million in Q1 2026, $30.6 million in Q4 2025, and $27.8 million in Q3 2025.